

Cephalon Announces Positive Results from a Pivotal Study of

Company on Target to File Supplemental New Drug Application in the Fourth Quarter Cephalon, Inc. (Nasdaq: CEPH) today announced positive results from a 12-week, Phase 3 clinical trial of FENTORA(R) (fentanyl buccal tablet) C-II in patients with breakthrough pain associated with a broad range of chronic non-cancer pain conditions. The study achieved statistical significance on the primary endpoint. Results across the 12 weeks of treatment showed both statistically significant and clinically relevant outcomes for patients with breakthrough pain who were already receiving and who were tolerant to opioid therapy for their underlying persistent pain. FENTORA is approved only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. "We are excited to complete our Phase 3 program with this third and final controlled study. These data show similar positive outcomes as those with FENTORA in treating breakthrough pain in opioid-tolerant patients with cancer, chronic neuropathic pain, and chronic low-back pain," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "We plan to submit these data to the Food and Drug Administration in the fourth quarter as part of our supplemental New Drug Application." About the Study The double-blind, placebo-controlled, variable dose Phase 3 trial included 148 patients. The primary endpoint was the Sum of Pain Intensity Differences from five to 60 minutes (SPID(60)) as assessed after 12 weeks of treatment. SPID(60) is a measure that assesses analgesic efficacy of a pain medication over the first 60 minutes after treatment.

About the Author

From www.oxfordshirebioscience.com:

Denver Pain Management offers a full range of advanced treatments for pain management, including diagnostic and therapeutic spinal injections.

The Pain Management Center provides care for thousands of hospitalized and ambulatory patients with acute, chronic and cancer.

Back pain is frequently the result of inadequate muscle strength, shortened muscles, poor posture, being overweight, poor bending and lifting.

Pain management clothing and products. Natural pain management for chronic pain, amputee phantom pain and sports related.

Let us help you to find some resources and professionals for pain management. Find a pain professional who is part of the American.

A resource for patients, families and health care providers on pain management options through the University of Michigan.

Chronic pain is defined as pain that persists for longer than three months. At any given time, around one third of Australians are in pain. Management.

The Arthritis Pain Center features information on dealing with chronic pain. Understanding Your Pain. Managing Your Pain. Take Medicines.

Source: <http://www.productsherbal.com>